ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Change In Receivables : $-17.5 Mil (TTM As of Sep. 2016)

View and export this data going back to 1994. Start your Free Trial

What is ARIAD Pharmaceuticals Change In Receivables?

ARIAD Pharmaceuticals's change in receivables for the quarter that ended in Sep. 2016 was $-9.9 Mil. It means ARIAD Pharmaceuticals's Accounts Receivable increased by $9.9 Mil from Jun. 2016 to Sep. 2016 .

ARIAD Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2015 was $-7.3 Mil. It means ARIAD Pharmaceuticals's Accounts Receivable increased by $7.3 Mil from Dec. 2014 to Dec. 2015 .

ARIAD Pharmaceuticals's Accounts Receivable for the quarter that ended in Sep. 2016 was $24.0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. ARIAD Pharmaceuticals's Days Sales Outstanding for the three months ended in Sep. 2016 was 47.54.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. ARIAD Pharmaceuticals's liquidation value for the three months ended in Sep. 2016 was $-389.3 Mil.

ARIAD Pharmaceuticals Change In Receivables Historical Data

The historical data trend for ARIAD Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARIAD Pharmaceuticals Change In Receivables Chart

ARIAD Pharmaceuticals Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Change In Receivables

Get a 7-Day Free Trial

-1.31

-7.09

-7.29

ARIAD Pharmaceuticals Quarterly Data
	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Change In Receivables	Get a 7-Day Free Trial															-1.06	-0.21	-5.92	-1.53	-9.87

ARIAD Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.5 Mil.

ARIAD Pharmaceuticals (NAS:ARIA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

ARIAD Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2016 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	23.975	/	46.016	*	91
=	47.54

2. In Ben Graham's calculation of liquidation value, ARIAD Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

ARIAD Pharmaceuticals's liquidation value for the quarter that ended in Sep. 2016 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	314.665	-	722.94	+	0.75 * 23.975	+	0.5 * 2.061
=	-389.3

ARIAD Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of ARIAD Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARIAD Pharmaceuticals Inc (NAS:ARIA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.ariad.com

ARIAD Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. The Company's first approved cancer medicine, Iclusig (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that it has developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company's competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.

Executives

Alexander J Denner	director	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Norbert G Riedel	director	BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Elona Esq. Kogan	officer: Sr. V. P. - General Counsel	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Manmeet Singh Soni	officer: EVP, CFO & Treasurer	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Timothy P Clackson	officer: President, R&D, CSO	C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jules Haimovitz	director	601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
Daniel M Bollag	officer: Sr. VP, Reg. Affairs & Quality	C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Hugh M Cole	officer: SVP, Chief Business Officer	C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
George Bickerstaff	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Paris Panayiotopoulos	director, officer: President and CEO	ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Anna Protopapas	director	MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Sarah J. Schlesinger	director	C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Massimo Radaelli	director	C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Martin J Duvall	officer: EVP, CCO	MGI PHARMA, INC., 5775 WEST OLD SHAKOPEE ROAD, SUITE 100, BLOOMINGTON MN 55437
Frank Haluska	officer: SVP, Clinical R&D, CMO	C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139

ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Headlines

From GuruFocus

ARIAD Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 08-10-2009

ARIAD Pharmaceuticals Inc. Reports Operating Results (10-K)

By gurufocus 10qk • 03-15-2011